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Abstract: Intravascular catheter-related infections are still a major problem in health care 
and are associated with significant morbidity, mortality, and additional cost. The formation of 
microbial biofilm on catheters makes these infections particularly complicated, as microbial 
cells that detach from the biofilm can lead to infection, and because these microorganisms 
are highly resistant to many antimicrobial agents; thus, catheter removal is often required to 
successfully treat infection. To reduce the risks of catheter-related infections, many strategies 
have been applied, such as improvements in aseptic insertion and post-insertion care practices, 
implantation techniques, and antibiotic coated or impregnated materials. However, despite 
significant advances in using these methods, it has not been possible to completely eradicate 
biofilm infections. Currently, nanotechnology approaches seem to be among the most promising 
for preventing biofilm formation and resultant catheter-related bloodstream infection (especially 
with multi-resistant bacterial strains). In this review, current knowledge about catheter technology 
and design, the mechanisms of catheter-related bloodstream infection, and the insertion and care 
practices performed by medical staff, are discussed, along with novel, achievable approaches to 
infection prevention, based on nanotechnology.
Keywords: catheter related infections, biofilm, nanotechnology
Introduction
Intravascular catheter- (IVC-) related infections lead to high morbidity and mortality 
for patients, and increase costs of health care.1 Infections develop when microorgan-
isms adhere to catheter surfaces and produce extracellular substances that facilitate 
adhesion (and provide a structural matrix) for forming biofilms.2 Following biofilm 
development, microbial cells from the biofilm maturate and can periodically disperse 
into the bloodstream, causing serious infections.2 Biofilms are resistant to host defence 
mechanisms and antibiotic agents, making the treatment of catheter-related infections 
more challenging. In order to prevent catheter-related infections, a large number of 
strategies and approaches have been developed, including strict hygienic procedures 
during catheter insertion and use; total or partial (tunneling) implantation of long-term 
catheters; surface modification of catheter biomaterials with antimicrobial coatings or 
impregnation; and antibiotic or antimicrobial locking solutions.2 However, it remains 
impossible to achieve a completely anti-adhesive catheter material since catheter sur-
faces can be rapidly covered by plasma and matrix proteins, on which bacteria display 
specific adhesions. The challenge of biofilm-related infections remains. Nanotechnolo-
gies, especially nanomaterials, are one of the more promising new strategies that aim 
to prevent biofilm infections in patients with IVCs.
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This review will summarize current knowledge about 
catheter-related bloodstream infections (CRBSIs), as well as 
the nanotechnologies in use, or in development, to prevent 
catheter-related infections occurring due to colonization and/
or biofilm formation on catheter surfaces. We also discuss 
the knowledge gained from microbial research in other 
medical and non-medical applications that may be helpful 
to understanding the IVC context. In addition, published 
theories and data regarding microbial colonization and bio-
film development, specifically related to IVCs, are reviewed. 
This review aims to provide baseline information for the 
future development of new and effective strategies to prevent 
catheter-related infections.
Catheter technologies  
and catheter design
Intravenous catheters have evolved considerably, from the 
early prototypes of goose quill, silver, glass, and steel tubes, 
to modern day polyurethane- and silicone-based models. 
The ideal catheter exhibits a high tensile strength, is soft 
and pliable, inherently chemical-resistant, biocompatible, 
and meets flow requirements. Common catheter materials 
include polyurethane, silicone, polyethylene and Teflon®. 
A comparison of the relevant characteristics of these catheter 
materials is shown in Table 1. Polyurethane catheters are 
now often the preferred material. They are highly biocom-
patible (therefore, well-tolerated by patients), compatible 
with the majority of drugs, and resistant to many chemi-
cals.3  Nevertheless, the repeated application of alcohol-
based cleaning agents potentially can perish the catheter. 
 Polyurethane is thromboresistant, and softens within the 
body. Therefore, mechanical trauma and irritation within 
the vein are reduced, compared against harder materials.4 
Other advantages of polyurethane are its tensile strength, 
multiple lumens, and smaller external diameters, which 
maximize blood flow in a vessel with catheter. Modern 
polyurethane catheters are now available as semirigid yet 
flexible materials, often used for short-term catheter access. 
They are sufficiently stiff for percutaneous insertion over a 
wire without splitting the sheath, yet soften in the body after 
insertion. Silicone catheters are also biocompatible and com-
patible with most drugs, as well as alcohol-based cleaning 
solutions, although they can be damaged by peroxide and 
some povidone-iodine solutions. Silicone is soft, pliable, and 
thromboresistant,4 but it has limited tensile strength, result-
ing in easy rupture, and it requires a restricted infusion flow 
pressure.5 Silicone catheters need insertion through a sheath 
or cannula. Other IVC materials such as polyethylene and 
Teflon® (tetrafluoroethylene-hexafluoropropylene) are less 
favorable catheter materials, and have nearly been replaced 
by polyurethane and silicone, since they are less biocompat-
ible, stiffer, and have poor flexibility.4 Teflon has also been 
shown to have higher infection rates, compared against the 
other three catheter materials.6
There are numerous types of IVC, with varying designs, 
for different functional requirements and durations of use. 
Short-term central venous catheters are usually made of 
polyurethane.7 They are relatively short tapered, open-ended 
mutilumen catheters, used for 3–10 days. Long-term central 
venous catheters may be used for months or years, and have 
a catheter portion “tunneled” or “cuffed” under the skin. 
Alternatively, totally implanted “ports” may be implanted 
into a central vein, and periodically accessed using a needle, 
for long-term therapy. Small, peripheral venous or arterial 
catheters are single lumen, and are also commonly made of 
polyurethane. Midline catheters are single or dual lumen, 
predominantly composed of silicone, and are used for 
2–4 weeks.8 Peripherally-inserted central catheters (PICCs) 
can be made of polyurethane or silicone, with single to 
triple lumen types available. They are recommended for 
mid-term therapy: from 6 weeks to 1 year.9 PICCs can be 
valved or non-valved. Non-valved PICCs are open-ended 
and require regular positive flushing after use, to prevent 
blood backflow causing occlusion.10 Valved PICCs contain 
a pressure-sensitive valve at the side of the distal end, which 
allows both fluid infusion and blood aspiration;10 therefore, 
Table 1 Comparison of catheter material characteristics
Polyurethane Silicone Polyethylene Teflon®
Biocompatiblity excellent excellent Fair Fair
Stiffness Softens in body Soft Stiff Stiff
ease of insertion Difficult Fair easy easy
ease of modifying Fair easy Difficult Difficult
Tensile strength excellent Fair excellent excellent
Flexibility Fair excellent Poor Poor
Coefficient of friction excellent Fair Good excellent
Infection rate Low Fair High High
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
18
1.
30
.6
7 
on
 2
2-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2013:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4455
Reducing IvC-related infection risk through nanotechnology
heparinized flushes are not required. Hemodialysis catheters 
are composed of silicone or polyurethane and can be cuffed, 
or non-cuffed, depending on the duration of usage. These 
catheters have large bores and relatively stiff constructions, 
to avoid wall collapse under negative pressure from pumped 
systems.11 The lumen has one end-hole and multiple side 
holes, to improve flows and mixing of blood. Two function-
ally separate catheters can be inserted in parallel, their tips 
lying slightly separated, in the same vein.11 Alternatively, 
a combined dual or triple lumen catheter can be used, which 
has a staggered design: one lumen positioned 3–5 cm above 
the other, to prevent recirculation of treated blood. To prevent 
thrombotic events occurring within this type of catheter, 
heparin locks are essential. Late catheter malfunction is often 
the consequence of fibrin deposition around the catheter tip – 
an unpredictable process, but one that occurs more frequently 
in some patients and less frequently in others.11
Catheter-related bloodstream 
infection
The use of IVCs is essential for the successful management 
of critically and chronically ill patients.12 However, CRB-
SIs have become a leading cause of health care-associated 
bloodstream infections, and are associated with substantial 
morbidity and mortality.13 More than 250,000 CRBSIs occur 
annually in the USA, with an attributable mortality ranging 
from 12%–25% in critically ill patients, and with an added 
cost ranging from US$4,000–$56,000.14,15
CRBSI is defined as 1) fever and other clinical manifes-
tations of bloodstream infection in a patient with an IVC; 
2) the presence of positive simultaneous quantitative blood 
cultures from the IVC and the peripheral vein, yielding the 
same organism; 3) no apparent source for the bloodstream 
infection, other than the catheter; and 4) positive semi-
quantitative catheter tip cultures with 15 colony forming 
units (CFUs) of the same microorganisms as isolated from 
the blood cultures. Alternatively, CRBSI can be diagnosed 
through simultaneous quantitative blood cultures, whereby 
the number of colonies isolated from the blood drawn through 
the IVC is at least three times greater (ratio: 3:1) than the 
number of colonies isolated from blood drawn via a periph-
eral vein, or from one of two different lumen-drawn blood 
cultures from multi-lumen catheters (“possible CRBSI”).1 
The differential between time-to-positivity of peripherally-
drawn blood cultures of 2 hours growth, and simultaneously 
drawn peripheral venous blood cultures, is also diagnostic 
of CRBSI.1
CRBSI most frequently develops in seriously ill patients 
admitted to hematology-oncology and intensive care units 
(ICUs) of acute care hospitals. The most commonly reported 
causative pathogens for CRBSI are coagulase-negative staph-
ylococci, Staphylococcus aureus, enterococci, and Candida 
spp. (Table 2).16,17 According to the US Centers for Disease 
Control and Prevention’s database, approximately 19% of 
CRBSI cases involve gram-negative bacilli.18 Antimicrobial 
resistance is a concern with all pathogens responsible for 
CRBSIs. It has been demonstrated that methicillin-resistant 
S. aureus (MRSA) accounts for more than 50% of all S. 
aureus isolated in ICUs – although the incidence of CRBSI 
caused by skin organisms (particularly MRSA) in ICUs 
has decreased in recent years, due to coordinated efforts in 
many countries to improve sterile insertion procedures to 
prevent insertion-related contamination of central venous 
catheters.16,17 By contrast, with regard to gram-negative rods, 
Table 2 Incidence rates of most commonly isolated pathogens from MNBSIs, and associated crude mortality rates, for patients in ICU 
and non-ICU wards 17
Pathogen CRBSI per 10,000  
admissions
Percentage of CRBSI Crude mortality (%)
Total 
(n=20,978)
ICU 
(n=10,515)
Non-ICU ward 
(n=10,442)
Total ICU Non-ICU 
ward
Coagulase-negative  
Staphylococcus
15.8 31.3 35.9 26.6 20.7 25.7 13.8
S. aureus 10.3 20.2 16.8 23.7 25.4 34.4 18.9
Enterococcus spp. 4.8 9.4 9.8 9.0 33.9 43.0 24.0
Candida spp. 4.6 9.0 10.1 7.9 39.2 47.1 29.0
Escherichia coli 2.8 5.6 3.7 7.6 22.4 33.9 16.9
Klebsiella spp. 2.4 4.8 4.0 5.5 27.6 37.4 20.3
Pseudomonas aeruginosa 2.1 4.3 4.7 3.8 38.7 47.9 27.6
Enterobacter spp. 1.9 3.9 4.7 3.1 26.7 32.5 18.0
Serratia spp. 0.9 1.7 2.1 1.3 27.4 33.9 17.1
Acinetobacter baumannii 0.6 1.3 1.6 0.9 34.0 43.4 16.3
Abbreviations: MNBSI, monomicrobial nosocomial blood stream infection; ICU, intensive care unit; CRBSI, catheter-related bloodstream infection. 
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the incidence of antimicrobial resistance to third-generation 
cephalosporins among Klebsiella pneumonia and Escherichia 
coli is increasing significantly, along with imepenem and 
ceftazidine reistance among Pseudomonas aeruginosa.18
It is believed that there are four pathways for bacteria to 
enter into the sterile bloodstream and cause catheter-related 
infections.16 The first is extraluminal contamination of the 
catheter with skin organisms, occurring during insertion, 
or migration of such organisms down the catheter tract 
while it is in place. This is the most common infection route 
for short-term catheters. The second route is intraluminal, 
involving contamination of catheter hubs and connectors 
through contact with the hands of hospital staff who use the 
catheter to install medicine or take blood. The third route is 
direct contamination of the catheter by bacteria circulating 
in the bloodstream; for example, following translocation of 
gastrointestinal flora through the intestinal wall. The fourth 
pathway is through contaminated infusate, which may occur 
at the manufacturing stage (intrinsic contamination), or 
during manipulation by health care staff when preparing or 
administering fluids (extrinsic contamination).
If contamination occurs, the initial microbial attach-
ment of bacteria onto the inner and outer surfaces of IVCs 
is almost inevitably followed by biofilm development and 
maturation, which is followed by dispersion of microbial 
cells from the biofilm into the bloodstream, causing CRBSI. 
Microorganisms embedded in biofilms typically present 
phenotypic and genotypic characteristics different to those 
grown planktonically.19 They are able to obtain and concen-
trate a number of different nutrients from the environment.19 
They are resistant to a number of antimicrobial agents, not 
only because the antimicrobials cannot penetrate into all the 
biofilm layers, but also because the organisms grow slowly 
and may then be resistant to immune defence mechanisms.20 
The biofilm mode can also facilitate dissemination of 
 organisms. Furthermore, microorganisms may exhibit dif-
ferent virulence phenotypes when growing within a biofilm; 
these phenotypes may not have been detected from IVCs in 
the past, because traditional hospital diagnostic tests, such 
as the semiquantitative roll-plate technique, used to culture 
catheter tip segments, involve growth of organisms on 
rich nutrient media, under planktonic conditions.21 Rather 
than being amorphous aggregates, biofilms are complex, 
structured communities in which physiological conditions, 
such as nutrient and oxygen availability, vary at differ-
ent depths.22 Therefore, the microorganisms at different 
depths are phenotypically, morphologically, and function-
ally different. Once biofilm infection occurs, the host will 
establish an immune response to antigens released from the 
biofilm. However, not only may the host’s immune system 
fail to eradicate the biofilm, it may also result in damage to 
surrounding tissues.
The pathogenesis of fibrin sheath formation from bio-
films is still not understood. After biofilm formation, fibrin 
and many other molecules, such as laminin, collagen, and 
even muscle cells, convert the biofilm to a mature sheath.23 
Metallic cations, such as magnesium, calcium, and iron, may 
stabilize the biofilm and facilitate biofilm development and 
bacterial growth.24 Catheter thrombosis on the fibrin sheath 
may be facilitated by platelet activation, decreased levels of 
protein C and antithrombin III, hyperfibrinogenemia, and 
homocysteine elevation. It has been demonstrated that the 
presence of catheter-related thrombosis increases the risk 
of CRBSI.25,26 Many patients require long- term IVCs, and 
attempts have been made to treat CRBSI without removing 
the IVC, with variable results. However, as understand-
ing of biofilm structure and function develops, it is clear 
why often the only solution to an infected IVC is catheter 
removal, which brings increased hospital costs, additional 
painful invasive procedures for patients, and interruption to 
medical therapy.
There are numerous recommended preventive strategies 
for clinicians to avoid CRBSIs, and these are supported by 
varying levels of evidence for their effectiveness. Strategies 
include issues of education, training, and staffing among 
health care providers who insert and maintain IVCs; selection 
of catheters and sites; hand hygiene and aseptic technique; 
maximal sterile barrier precautions on insertion; pre-
insertion skin preparation; catheter site dressing regimens; 
patient cleansing (bathing); catheter securement devices; 
 antimicrobial/antiseptic impregnated catheters (for .5 day 
catheters, if other education-based interventions have not 
been effective); antibiotic/antimicrobial ointments for dialy-
sis catheter sites; antimicrobial lock solutions for patients 
with repeated CRBSI and long-term IVCs; at least weekly 
replacement of IV infusion tubing; disinfection of needle-
less connectors prior to use; and replacement of connectors 
at least every 72 hours.16
The majority of recommended CRBSI prevention strate-
gies target improved clinical practices among hospital staff, 
rather than technological approaches. The most successful 
development in recent years has been the implementation 
of central venous catheter “care bundles”, which are qual-
ity campaigns targeting CRBSI in ICUs. Such initiatives 
comprise simultaneous implementation, and focus on con-
sistent use of, five best practice procedures, in the context 
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of key stakeholder championship, with ongoing audit and 
feedback of infection rates to staff. Numerous national and 
international campaigns have been launched, stemming 
from the successful Keystone ICU Project in Michigan, 
USA.27 The bundles focus predominantly on the insertion 
procedure, including hand hygiene and maximal sterile bar-
rier precautions by the inserter; decontamination of the skin 
site pre-insertion (with 2% chlorhexidine gluconate in 70% 
alcohol); avoidance of the femoral insertion site, if possible; 
and removal of unnecessary IVCs. It is widely agreed that 
such campaigns have greatly reduced, but not eliminated, 
CRBSIs, particularly those stemming from extra-luminal 
contamination, occurring during the insertion procedure.16 
There is a resultant need to now focus on maintaining those 
successful infection-prevention practices, and extending 
them outside of the ICU setting, while adding improvements 
in post-insertion care, to focus on intraluminal colonization-
related infections.28
Nanotechnology
The foundation material of the IVC can also be coated or 
impregnated with antibiotic or antiseptic agents, to reduce 
the risk of CRBSIs. Despite significantly higher initial 
purchase costs, such catheters have been associated with an 
overall decrease in hospital costs associated with treating 
CRBSIs. Comparing infection rates of non-impregnated 
and impregnated catheters, results indicate that impregna-
tion could reduce catheter-related infection rates in various 
settings and countries (Table 3). However, concerns exist 
about the potential for development of antimicrobial/anti-
biotic resistance. Currently, antiseptic/antibiotic catheters 
are only recommended for short-term use if the CRBSI 
rate does not decrease, despite adherence to basic preven-
tion measures.29 While antiseptic/antibiotic-impregnated 
intravascular catheters have been shown to decrease the 
rate of CRBSI in patients with short-term catheters, the 
benefit in patients with long-term catheters remains unclear. 
There is additional concern about the potential to generate 
multidrug-resistant organisms. In all, none of these strate-
gies seems able to totally prevent CRBSIs; nanotechnology 
might bring new hope.
The use of antimicrobial agents was extended to IVC 
dressing. In one randomized multicenter assessor-blind 
trial, 1,636 patients with catheter dressings, with or 
without chlorhexidine-impregnated sponges as part of 
the standard, transparent, semipermeable polyurethane 
IVC dressing, were evaluated.30 A total of 3,778 catheters 
were enrolled (28,931 catheter-days). The chlorhexidine- 
impregnated sponge dressings decreased rates of major 
catheter-related infections (0.6 per thousand catheter-days 
versus [vs] 1.4 per thousand catheter-days; hazard ratio 
[HR], 0.39; 95% confidence interval [CI], 0.17–0.93 
Table 3 Rates of catheter-related colonization and bloodstream infection associated with non-impregnated and antiseptic/antibiotic-
impregnated intravascular catheters
Catheter type Study Country Setting Number Catheter  
colonization
Catheter-related 
bloodstream  
infection
Non-impregnated Hanna et al37 USA Single center 174 n/a 14 (8.0%)a
Ostendorf et al34 Germany Single center 94 31 (33%) 7 (7%)b
Jaeger et al102 Germany Single center 55 9 (16.4%) 8 (14.5%)c
Sheng et al103 Taiwan Single center 122 25 (20.5%) 2 (1.6%)d
Lorente et al104 Spain Single center 287 n/a 12 (4.18%)e
Impregnated with
 Silver sulfadiazine/chlorhexidine walder et al33 Switzerland Multiple centers 1,544 n/a 65 (4.2%)
Ostendorf et al34 Germany Single center 90 11 (12%) 3 (3%)b
Jaeger et al102 Germany Single center 51 5 (9.8%) 1 (1.96%)c
Darouiche et al36 USA Multiple centers 382 87 (22.8%) 13 (3.4%)f
 Minocycline/rifampin Darouiche et al36 USA Multiple centers 356 28 (7.9%) 1 (0.3%)f
Hanna et al37 USA Single center 182 n/a 3 (1.65%)a
Sheng et al103,d Taiwan Single center 113 9 (7.1%) 1 (0.9%)d
Lorente et al104 Spain Single center 238 n/a 0e
Notes: aOdds ratio for CRBSI (catheter-related bloodstream infection): 0.1 for minocycline/rifampin, compared against non-impregnated catheters; P,0.001; bodds ratio 
for colonization: 0.36 silver sulfadiazine/chlorhexidine-impregnated, compared against non-impregnated catheters; P=0.01. No significant differences for CRBSI; codds ratio 
for colonization: 0.46 silver sulfadiazine/chlorhexidine-impregnated, compared against non-impregnated catheters; P=0.035. Odds ratio for CRBSI: 0.12 silver sulfadiazine/
chlorhexidine-impregnated, compared against non-impregnated catheters, P=0.02; dodds ratio for colonization: 0.34 silver sulfadiazine/chlorhexidine-impregnated, compared 
against non-impregnated catheters; P=0.006. No significant differences for CRBSI; eodds ratio for CRBSI: 0.13 for minocycline/rifampin, compared against non-impregnated 
catheters; P,0.05; fodds ratio for colonization: 0.31 for minocycline/rifampin, compared against silver-sulfadiazine/chlorhexidine impregnated catheters; P,0.001. Odds ratio 
for CRBSI: 0.08 for minocycline/rifampin, compared against silver-sulfadiazine/chlorhexidine impregnated catheters; P,0.0001.
Abbreviation: n/a, not available.
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per thousand  catheter-days; P=0.03) and CRBSIs (0.40 
per thousand catheter-days vs 1.3 per thousand catheter-
days; HR, 0.24;CI, 0.09–0.65 per thousand catheter-days; 
P,0.001).30 A randomized controlled study of a chlorhex-
idine-impregnated sponge dressing in 74 children showed 
that it could reduce the rates of catheter colonization (HR, 
0.61; CI, 0.3716–1.023; P=0.0446), but there was no 
statistical difference in CRBSIs when compared with no 
antimicrobial dressings.31 One possible reason is that the 
study was underpowered to detect these differences.
Catheters whose outer surfaces are impregnated with 
chlorhexidine and silver sulfadiazine have been confirmed to 
reduce the risks of CRBSIs.32 They remained effective when the 
median duration of insertion time was less than 7 days (median, 
6 days; interquartile range [IQR] 5.2–7.5 days) compared 
with control catheters (median 12 days; IQR 7.8–20 days).33 
Second-generation catheters are manufactured with chlor-
hexidine coating on the internal surfaces, extending into the 
extension set and hubs, while the external luminal surface is 
coated with chlorhexidine and silver sulfadiazine.34,35 Although 
it has been shown that second-generation catheters can reduce 
catheter colonization, a significant decrease of the CRBSI rate 
was not detected.34,35 Catheters impregnated with minocycline 
and rifampin on external and internal surfaces were associated 
with lower risks of CRBSI, compared against catheters with 
external coating of chlorhexidine and silver sulfadiazine.36 
Silicone catheters impregnated in both the external and internal 
surfaces with a combination of minocycline and rifampin can 
decrease the rate of CRBSIs, compared against controls, even 
with an average dwell time of 60 days.37 No correlation has 
been shown between the usage of minocycline- and rifampin-
impregnated catheters and the development of antimicrobial 
resistance, or the selection of resistant flora.
Thrombus proteins can also increase bacterial attachment 
on IVCs, and have been associated with CRBSIs. It has been 
shown that the formation of a fibrin sheath around the catheter 
greatly increases catheter colonization.38 Heparin-coated 
catheters were reported to be able to decrease thrombosis, 
and the risks of CRBSIs.39 However, the potential benefits 
of heparin, or heparin-coated catheters, must be balanced 
against the small, but important, risk of heparin-induced 
thrombocytopenia. Because heparin solutions contain pre-
servatives with antimicrobial activity, it is unknown whether 
a decrease in the CRBSI rate is due to decreased thrombus 
formation, or due to the preservative.
Many metal ions have antimicrobial activity. Among 
these, silver has the highest level of toxicity for microor-
ganisms and the lowest toxicity for animal cells.40 Silver 
nanoparticles are clusters of silver atoms that exhibit strong 
bactericidal activity, against both gram-positive and gram-
negative bacteria.41 Silver ions can inhibit replication of 
bacteria (through binding to the microbial DNA) and/or 
switch off important enzymes, leading to microbial death 
(Figure 1).42 It has also been suggested that silver nanopar-
ticles could prevent biofilm formation, since they have an 
affinity for proteinaceous compounds, where they combine 
with the sulfhydryl group, inducing protein denaturation 
and corresponding enzyme inactivation.43 As yet, silver 
nanoparticles have not been shown to cause microbial resis-
tance, in contrast to increasing microbial resistance towards 
many traditional antimicrobial agents, and the consequent 
development of resistant strains. A possible explanation is 
Bacterium
Bacterium takes up Ag+
Bacterium damaged
Bacterium destroyed
Figure 1 Mechanisms of silver ions against bacterium.
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that silver nanoparticles do not only exert their antibacterial 
effects at a particular site, but at several locations, such as 
the bacterial wall, during proteosynthesis, and in DNA.41 
Silver nanoparticle-coatings could exert their antimicrobial 
properties in vivo, by slowly releasing silver ions.44 Silver 
nanoparticles enable a constant local supply of silver ions at 
the coating–tissue interface, and also allow improved contact 
with the microorganisms.45 Therefore, the prevention of 
microbial adhesion and biofilm formation is more prolonged 
than with other antimicrobial approaches. Thus, IVC coating 
with silver nanoparticles could protect both outer and inner 
surfaces of catheters through continuous release of silver 
ions, to provide antimicrobial activity.
In addition to use in catheters, nanotechnology offers 
promise in reducing post-insertion intraluminal IVC coloni-
zation related to staff handling of IVC needleless connectors. 
Needleless connectors are used to cap off IVCs temporarily 
not in use, to connect infusion administration sets to the 
catheter, and to provide an access point for administration 
of medicines and withdrawal of blood specimens. Recently, 
connector devices have increasingly attracted the attention 
of commercial manufacturers and researchers alike.46 Many 
such devices have recently entered the market, with a variety 
of internal engineering. Some needleless connectors incor-
porate a valve, to prevent backflow of blood and intravenous 
fluids into the connector, which aims to prevent catheter 
occlusion or thrombosis.47,48 However, many studies suggest 
that some valved needleless connectors actually increase the 
risk of CRBSI. Jarvis et al compared split septum needleless 
connectors against mechanical valve-type needleless connec-
tors, and demonstrated that mechanical valve needleless con-
nectors have higher CRBSI rates, despite similar bloodstream 
infection surveillance, definitions, and prevention strategies.49 
One investigation found CRBSIs increased after a switch 
from a negative fluid displacement to a positive displacement 
mechanical valve.50 However, in another observational study, 
a switch from a negative displacement mechanical valve to 
a different, luer-activated positive displacement mechanical 
valve led to a significant decrease in CRBSIs.51 Definitive 
reasons for these sometimes conflicting results with different 
types of needleless connectors are still unknown. Regardless 
of their make, frequent handling, and accessing of catheter 
hubs by staff, needleless connectors and injection ports have 
great potential to put patients at risk of primary bloodstream 
infections, since they facilitate entry of bacteria into the con-
nector and fluid path.52 Research from Donlan et al showed 
a high incidence of biofilm formation on the interior surface 
of valved connectors that had been used clinically.53
As a consequence, increasing numbers of studies are 
being added to the literature on reducing CRBSIs, related to 
use of needleless connectors. It has been shown that exter-
nal disinfection of the devices with chlorhexidine/alcohol, 
rather than alcohol alone, can reduce IVC colonization.47,54 
In addition, the time spent on applying the disinfectant is 
important. Results from one study suggest that wiping the 
connector with 70% isopropyl alcohol for 3–5 seconds did 
not adequately disinfect the septal surface.55 Many studies 
have also shown that conventional disinfection may not be 
able to prevent entry of microorganisms, if significant con-
tamination of the membranous septum is present prior to the 
injection or infusion of fluids.56,57
A novel silver nanoparticle-coated connector has been 
introduced recently. Designed as a single use, disposable 
valved connector, it is constructed of polycarbonate. However, 
with the exception of the silicone membranous septum, the 
entire surface of the connector, including the entirety of the 
internal fluid path and the external casing, has a silver nano-
particle coating.46 Silver nanoparticles are stably imbedded 
in the polycarbonate matrix, and release minute quantities of 
bactericidal ionic silver from the surface, into the fluid path.46 
Simulation studies have shown that the total amount of ionic 
silver eluted into the fluid pathway (with continuous infusion), 
and infused into the patient, is far less than the level of silver 
exposure considered to pose a risk to human health.58,59 Most 
of the silver absorbed is excreted in feces and urine. Therefore, 
silver nanoparticle coating might be safely applied, to prevent 
contamination and the formation of biofilm on the internal 
surface IVCs. This has great potential to reduce the risk of 
CRBSI, but has not yet been studied in clinical trials. In 2010, 
Maki examined the efficiency of a silver nanoparticle-coated 
connector, compared against non-medicated connectors, in 
reducing fluid path colonization, by filling these connectors 
with six bacteria: Staphylococcus epidermidis, methicillin-
resistant Staphylococcus aureus, vancomycin-resistant 
Enterococcus, Enterobacter cloacae, Pseudomonas aerugi-
nosa, amd Candida albicans.46 After 24 hours and 72 hours 
of incubation, the remaining viable microorganisms were 
quantified, and compared with concentrations in control 
connectors. The biofilm formation of Enterobacter cloacae 
on silver nanoparticle-coated connectors was also examined, 
concluding that more than 99% of bacteria were killed and 
biofilm formation was also completely  suppressed.46 However, 
human bodies are much more complex than the models used 
in these studies, and large clinical trials are required to assess 
the clinical efficacy and safety of silver nanoparticle-coated 
connectors for preventing CRBSIs.
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Another advance could be in the use of liposomes, which 
are artificially prepared vesicles, made of a lipid biolayer, 
that can be used as drug carriers, especially against coloniz-
ing microorganisms. Liposomes can target the matrix (or 
biofilm) by specific attachment, allowing drugs to be released 
in the vicinity of the microorganisms (although, in the case 
of microbial cell adhesion to human cells, there is a need for 
further knowledge regarding the ability of this system to pre-
vent microbial adhesion but not affect adhered native cells).60 
Therefore, this nanotechnology is a promising research area, 
but it requires more research to fully understand the mecha-
nism behind the antimicrobial activity. However, several 
non-clinical studies have been performed on the interaction 
between liposomes and bacterial biofilms. Halwani et al 
showed that liposomes were very effective in eradicating 
antibiotic-resistant P. aeruginosa isolates growing in a 
planktonic or biofilm community.61 DiTizio et al developed 
a liposomal hydrogel system that significantly reduced bacte-
rial adhesion to silicone catheters. The system consists of a 
polyethylene glycol–gelatin hydrogel, in which liposomes 
containing the antibiotic ciprofloxacin are sequestered.62 
Liposomal antimicrobial lock therapy can potentially be 
considered as a possible alternative to catheter removal.63 
This technique opens new perspectives for the development 
of novel antimicrobial catheters.64
Polymer drug delivery systems are based on nanocarriers 
that are formed by mixing polymeric chemical compounds 
with drugs, to form large and complex molecules that carry 
the drug across physiological barriers.65 Polymeric micro-
spheres, polymer micelles, and hydrogel-type materials have 
been shown to be effective nanocarriers, for enhancing drug 
targeting specificity, lowering systemic drug toxicity, improv-
ing treatment absorption rates, and providing protection for 
the pharmaceuticals against biochemical degradation.66 In 
addition, this system has the possibility to add a pore-forming 
polymer, which can increase the amount of drug able to be 
loaded into the carrier.67 It has been shown that polymeric 
matrices can be mixed with different antimicrobial agents 
to prevent bacterial colonization and biofilm formation on 
medical devices.65 This system possesses features that are 
potentially amenable to the manufacture of antimicrobial 
medical devices, including IVCs.68 However, in vivo studies 
are yet to be performed, to test the efficacy of this antibiotic 
delivery carrier system in reducing bacterial colonization 
and biofilm formation on catheters.
The use of bacteriophages to control CRBSIs caused by 
biofilms has advantages over treatment with other conven-
tional antimicrobial agents, since phages have very strong 
bactericidal activity and can replicate at the site of infection.69 
It was reported that a progeny phage could treat a biofilm 
formation, due to its ability to propagate radially throughout 
a biofilm phage, to infect adjacent cells, and degrade the bio-
film matrix (Figure 2).70 In addition, it has been demonstrated 
that some phages are able to produce enzymes that hydrolyze 
and degrade the extracellular polymeric matrix of biofilms 
(Figure 2).70 A phage active against S. epidermidis, incor-
porated into a hydrogel coating on a catheter, significantly 
reduced biofilm formation on catheter surfaces.71 Recently, 
Fu et al studied the effect (in vitro) of pre-treating hydrogel-
coated catheters with P. aeruginosa phages, and observed 
a significant reduction of biofilm formation.72 This shows 
that the combination of two nanotechnological approaches 
can further reduce IVC biofilm formation72. However, prior 
to the use of a phage in humans, there are other aspects to 
be considered, such as, bacterial resistance to phage, phage 
inactivation by the human immune system, endotoxins in 
impure phage, and virulence genes encoded by the phage 
that can be incorporated into the host bacterial genome.70 The 
application of phage mixtures, or engineered phages, might 
provide better solutions for these problems.
The bioelectric effect is an approach that uses electri-
cal current to prevent biofilm formation and to enhance the 
activity of antimicrobials against established biofilms.73 The 
activity of antimicrobial agents against biofilm microorgan-
isms is enhanced through a relatively weak and continuous 
electrical current.73 However, there are few published in 
vivo studies on using electrical current to prevent medical 
device-related infection. Del Pozo et al introduced a new 
concept – the electricidal effect – by demonstrating dose- and 
time-dependent killing of S. epidermidis biofilms after pro-
longed exposure to low-intensity direct electrical current.74 
The electricidal effect was also tested in vivo, in a rabbit 
model of S. epidermidis chronic foreign body osteomyelitis, 
which confirmed the bactericidal activity of low amperage 
electrical current against bacterial biofilms.75 These results 
highlight the possibility of applying this therapy to different 
medical devices, including IVCs.
Safety and tolerability
The fundamental safety of health care technology is estab-
lished by the manufacturer, and certified by the relevant 
national regulatory body for medical drugs and devices (eg, 
Australian Therapeutic Goods Administration, US Food and 
Drug Administration, UK Medicines and Healthcare products 
Regulatory Agency). Efficacy in the clinical setting is tested 
in trials, as described earlier in this paper. However, the safety 
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of any device in the clinical setting also relies on adherence 
to the manufacturer’s guidelines, and competency of the end 
user: the clinician. Sadly, a plethora of research has identified 
a common, large variability in clinical practice and outcomes, 
when it comes to IVC insertion and aftercare.76–80
Improved patient outcomes for IVC insertion have been 
associated with dedicated IVC teams, and clinicians with 
improved skills and increased competencies, as a conse-
quence of effective training and procedural volume.81–84 
In addition, research has demonstrated that clinicians with 
minimal experience of inserting central venous catheters have 
a higher risk of complications arising.85 Improving and stan-
dardizing IVC practices, using multi-modal interventions, 
has demonstrated a significant reduction in infection rates 
(2.7 per thousand catheter-days reduced to 0 per thousand 
catheter-days, at 3 months post-intervention; P#0.002) 
(7.7 per thousand catheter-days reduced to 1.4 per thousand 
catheter-days, at 18 months post-intervention; P#0.002).27 
Furthermore, the results of a prepost study of a post-insertion 
bundle of evidence-based cares, such as appropriate dress-
A
B
Pretreatment
Post-treatment
Phage
Bacterial cell
Cell lysis and
release of progeny
phage
Cell lysis and
release of progeny
phage Detached biofilm cells
Hydrolysis of 
biofilm EPS by
phage-produced
deploymerase
Catheter
Biofilm EPS
Hydrogel
containing
phage
Biofilm treated with phage
Catheter
Figure 2 Mechanisms of hydrogel catheter coated with phage on (A) prevention of bacterial attachment on its surfaces, and (B) treatment of existing biofilm on catheter 
surfaces.
Note: Reprinted from Trends Microbiol, 17, Donlan RM, Preventing biofilms of clinically relevant organisms using bacteriophage, 66–72, Copyright (2009), with permission 
from elsevier.70 
Abbreviation: ePS, extracellular polymeric substance.
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ings, suggested a reduction in CRBSI from 5.7 per thousand 
catheter-days to 1.1 per thousand catheter-days.28 Another 
study, on the impact of the introduction of evidence based 
guidelines on peripheral venous catheter practice, was also 
associated with a reduction in infection rates, as well as with 
other improvements, including: completed insertion records 
(76% vs 58%; P,0.01), correct and sterile fixation localized 
(92% vs 80%; P,0.05), and catheter complications (4% vs 
15%; P,0.01).86
The significance of these studies is that they demon-
strate the positive impact of evidence-based “best prac-
tice” principles and systems, in guiding the insertion and 
care of IVCs. However, ensuring clinician understanding, 
acceptance, and adherence to recommended practice is 
challenging beyond the trial research setting. It involves 
a careful and strategic combination of staff education and 
the implementation of systems that promote best practice. 
Staff need to be educated not only about the clinical prob-
lem and related risks, but also about research methodol-
ogy and levels of evidence. However, in acknowledging 
the difficulty of achieving adequate compliance levels in 
practice, and understanding the fallibility of humans, we 
need to minimize risk and harm through forced decision 
making systems, or use of technology and equipment 
that negate clinician choice, and error (eg, central venous 
catheter insertion trolleys, or pre-filled flush syringes) 
and protect the patient (eg, impregnated catheters and 
nanotechnology).
Some clinicians, and even academics, believe that 
increased use of guidelines or standardized systems reduces 
and devalues clinical judgment. But, accompanying the 
freedom of clinical judgments is the risk of inappropriate 
judgment and error.87,88 Clinical judgment is not adequately 
accounted for in a systems analysis approach that may 
oversimplify health professionals’ choices, and so, within 
clinical practice. a tradeoff exists between forced choice and 
free-thinking design.89
Patient-focused perspectives
The financial cost of treating CRBSI is well documented. 
The US Institute for Healthcare Improvement has quanti-
fied the extra cost associated with each CRBSI episode at 
US$25,000–$55,000, which included an extension of the 
admission by 7 days, on average. The CRBSI-associated 
mortality rate ranges between 12%–25%.90 However, the 
“cost” to patients is less well documented. What is the 
impact of extended hospital stay (sometimes in isolation), 
the discomfort associated with local and systemic infection 
and related treatment, including ongoing surveillance and 
laboratory and radiological examinations?
There is a paucity of research describing the impact of 
CRBSI on the individual patient. Studies that have explored 
patients’ experiences of being nursed in single room isolation, 
due to infection while in hospital, have identified adverse 
effects including boredom, lowered or disturbed mood, and 
feelings of stigma, along with anxiety about passing the infec-
tions to relatives and carers.91–94 An integrated review of nine-
teen studies that explored patients’ experiences of infection 
and/or isolation identified some key common themes. These 
included a perceived lack of consistent information about the 
infection, poor understanding of the infection by health care 
staff, associated fear and stigma, and isolation.95
One small, qualitative study explored the patients’ 
experiences of CRBSI.96 In this study patients (n=18) were 
somewhat confident about asking staff about health care-
associated infection and related infection control issues. But, 
on the whole, patients were reluctant to question or challenge 
staff, because they did not want to alienate themselves. Most 
patients stated that they received little or no information about 
their infection, until later in their admission, if at all. Patients 
believed that low staffing levels, the use of temporary (bank) 
nursing staff, and poor cleanliness were causes of infection. 
While some patients were resigned to the potential risk of 
acquiring an infection in hospital, others dreaded it. There 
was no discussion about how each patient experienced the 
infection itself, its treatment, and sequelae.
There are few studies also to have examined patient 
experience of intravenous (IV) therapy or devices. An 
older paper discussed the potential stress associated with 
IV therapy, and suggested a number of potential causes, 
using case studies as references.97 The author identified three 
principal sources of anxiety about IV therapy: fear of pain, 
fear of needles, and fear of confinement. Having identified 
these factors, the author proposed a range of strategies and 
approaches for minimizing the stress. These included projec-
tion of confidence and competence by the clinician inserting 
or caring for the IV device, and the use of diversion tactics, 
for some patients, or detailed explanations of the procedure, 
equipment, and implications of therapy, for others.
Other research about the patient experience of IV therapy 
and devices comes from the community setting.98–101 In a US 
study conducted using interviews, patients spoke positively 
about the independence and autonomy that home-based 
IV therapy afforded them, compared against regular in-
hospital treatment. They valued the expertise and support 
of clinicians associated with the service. But patients also 
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reflected on the inflexibility of some clinicians and/or guiding 
protocols, and (sometimes) the use of “blaming or accusatory 
language” by staff, such as “poor access” or “bad veins”.100 
An Australian study of home-based IV therapy patients 
echoed similar feelings of independence and liberation in 
patients who had formerly been required to attend hospital 
for IV therapy – of experiencing feelings of “getting their 
life back”. When it is well managed and well supported, 
infectious outcomes of home-based IV therapy and patient 
self-management of IVs have been shown to be equivalent 
to, if not better than, clinician-controlled care. The incidence 
of catheter-related infections was significantly reduced in the 
patient education group (2.55 per thousand catheter-days) 
compared against a control group, with standard care (5.91 
per thousand catheter-days) (P,0.01).101
The significance of these studies’ results is that they 
demonstrate patients’ acceptance of, and willingness to 
embrace, health care technology. Future, trial-based research 
should incorporate patient evaluation and satisfaction in 
study protocols.
Conclusion
Catheter-related infections remain a major problem in health 
care, being associated with significant morbidity, mortality, 
and additional medical cost. Microbial biofilm formation 
makes these infections more complicated, as microbial cells 
detached from the biofilm can lead to acute infection, and 
these microorganisms are highly resistant to a large number of 
antimicrobial agents. New nanotechnologies are being devel-
oped in order to overcome problems associated with bacterial 
or fungal biofilm formation. The nanotechnology approach 
seems to be one of the most promising research fields for 
preventing biofilm formation and catheter-related infection, 
especially against multiresistant strains. However, these will 
never completely eradicate CRBSI, without additional and 
ongoing efforts to ensure health professionals consistently 
adhere to infection prevention measures. In addition, the 
patient’s experience and acceptance of CRBSI avoidance 
strategies, including nanotechnologies, must be considered, 
to maximize the success of such prevention measures.
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